Compare Repligen Corporation Common Stock (RGEN) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Sprott Uranium Miners ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Sprott Uranium Miners ETF trades at $42.21 (market cap $1.78B). The key difference: Repligen Corporation Common Stock is far larger — about 6.3× Sprott Uranium Miners ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Sprott Uranium Miners ETF for 62 Days on average.
| RGEN | URNM | |
|---|---|---|
Market Cap | $11.14B | $1.78B |
Volume | 1,259,263 | 1,008,269 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $194.57 | $83.99 |
52-Week Low | $102.87 | $42.42 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
URNM trades at $44.51, down 1.44% on the day, with a bearish technical signal from moving averages and oscillators. Recent news highlights uranium's role in AI energy demand and nuclear expansion, but financial ratios are unavailable. The ETF tracks uranium miners, with support at $43 and resistance at $46.
Long-term prospects are supported by nuclear energy growth and AI power needs, but short-term price volatility and lack of fundamental data pose risks. Investor sentiment is mixed, with bullish articles on uranium's future but technical indicators suggesting caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
